The clinical trial report, “Pulmonary Arterial Hypertension - Global Clinical Trials Review, 2026" provides an overview of Pulmonary Arterial Hypertension Clinical trials scenario. This report provides top line data relating to the clinical trials on Pulmonary Arterial Hypertension. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The analyst Clinical Trial Reports are generated using the analyst’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Report Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
Table of Contents
- Report Guidance
- The analyst Clinical Trials Report Coverage
- Clinical Trials by Region
- Clinical Trials and Average Enrollment by Country
- Top Five Countries Contributing to Clinical Trials in Asia-Pacific
- Top Five Countries Contributing to Clinical Trials in Europe
- Top Countries Contributing to Clinical Trials in North America
- Top Five Countries Contributing to Clinical Trials in Middle East and Africa
- Top Five Countries Contributing to Clinical Trials in Central and South America
- Clinical Trials by G7 Countries: Proportion of Pulmonary Arterial Hypertension to Cardiovascular Clinical Trials
- Clinical Trials by Phase in G7 Countries
- Clinical Trials in G7 Countries by Trial Status
- Clinical Trials by E7 Countries: Proportion of Pulmonary Arterial Hypertension to Cardiovascular Clinical Trials
- Clinical Trials by Phase in E7 Countries
- Clinical Trials in E7 Countries by Trial Status
- Clinical Trials by Phase
- In Progress Trials by Phase
- Clinical Trials by Trial Status
- Clinical Trials by End Point Status
- Subjects Recruited Over a Period of Time
- Clinical Trials by Sponsor Type
- Prominent Sponsors
- Top Companies Participating in Pulmonary Arterial Hypertension Therapeutics Clinical Trials
- Prominent Drugs
- Latest Clinical Trials News on Pulmonary Arterial Hypertension
- Dec 12, 2025: Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR (sotatercept) in Adults with Pulmonary Arterial Hypertension
- Dec 08, 2025: Zymedi Announces "Rapaprutug" as the International Nonproprietary Name (INN) for ZMA001
- Dec 08, 2025: Cereno Scientific Receives FDA Clearance to Initiate Global Phase IIb Trial of CS1 in Pulmonary Arterial Hypertension (PAH)
- Dec 08, 2025: Cereno Scientific Receives FDA Clearance to Initiate Global Phase IIb Trial of CS1 in Pulmonary Arterial Hypertension
- Dec 02, 2025: Tiakis Biotech Successfully Completes Data Package to Advance Tiprelestat Into Phase II Clinical Trial in PAH
- Nov 20, 2025: Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
- Nov 14, 2025: Initiation of a Phase II Clinical Trial for ACCRUFeR (Ferric Maltol) for the Treatment of Pulmonary Arterial Hypertension (PAH) in Japan.
- Nov 12, 2025: Calcimedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for PAH
- Nov 10, 2025: Cereno Scientific Submits Phase IIb Trial Protocol for CS1 in Pulmonary Arterial Hypertension (PAH) to the U.S. FDA
- Oct 30, 2025: MSD Reinforces Its Commitment to Research and Advancement of Cardiorespiratory Diseases
- Clinical Trial Profile Snapshots
- Appendix
- Abbreviations
- Definitions
- Research Methodology
- Secondary Research
- About the Analyst
- Contact the Publisher
- Source
- Pulmonary Arterial Hypertension Therapeutics, Global, Clinical Trials by Region, 2026*
- Pulmonary Arterial Hypertension Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*
- Pulmonary Arterial Hypertension Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*
- Pulmonary Arterial Hypertension Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2026*
- Pulmonary Arterial Hypertension Therapeutics Clinical Trials, Europe, Top Five Countries, 2026*
- Pulmonary Arterial Hypertension Therapeutics Clinical Trials, North America, Top Countries, 2026*
- Pulmonary Arterial Hypertension Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2026*
- Pulmonary Arterial Hypertension Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2026*
- Proportion of Pulmonary Arterial Hypertension to Cardiovascular Clinical Trials, G7 Countries (%), 2026*
- Pulmonary Arterial Hypertension Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*
- Pulmonary Arterial Hypertension Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*
- Proportion of Pulmonary Arterial Hypertension to Cardiovascular Clinical Trials, E7 Countries (%), 2026*
- Pulmonary Arterial Hypertension Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*
- Pulmonary Arterial Hypertension Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*
- Pulmonary Arterial Hypertension Therapeutics, Global, Clinical Trials by Phase, 2026*
- Pulmonary Arterial Hypertension Therapeutics, Global, Clinical Trials In Progress by Phase 2026*
- Pulmonary Arterial Hypertension Therapeutics, Global, Clinical Trials by Trial Status, 2026*
- Pulmonary Arterial Hypertension Therapeutics Clinical Trials, Global, by End Point Status, 2026*
- Pulmonary Arterial Hypertension Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
- Pulmonary Arterial Hypertension Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2026*
- Pulmonary Arterial Hypertension Therapeutics Clinical Trials, Global, Key Sponsors, 2026*
- Pulmonary Arterial Hypertension Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*
- Pulmonary Arterial Hypertension Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*
- Pulmonary Arterial Hypertension Therapeutics, Global, Clinical Trials by Region (%), 2026*
- Pulmonary Arterial Hypertension Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*
- Pulmonary Arterial Hypertension Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*
- Pulmonary Arterial Hypertension Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2026*
- Pulmonary Arterial Hypertension Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2026*
- Pulmonary Arterial Hypertension Therapeutics Clinical Trials, North America, Top Countries (%), 2026*
- Pulmonary Arterial Hypertension Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2026*
- Pulmonary Arterial Hypertension Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2026*
- Proportion of Pulmonary Arterial Hypertension to Cardiovascular Clinical Trials, G7 Countries (%), 2026*
- Pulmonary Arterial Hypertension Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*
- Pulmonary Arterial Hypertension Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*
- Proportion of Pulmonary Arterial Hypertension to Cardiovascular Clinical Trials, E7 Countries (%), 2026*
- Pulmonary Arterial Hypertension Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*
- Pulmonary Arterial Hypertension Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*
- Pulmonary Arterial Hypertension Therapeutics, Global, Clinical Trials by Phase (%), 2026*
- Pulmonary Arterial Hypertension Therapeutics, Global, Clinical Trials In Progress by Phase, 2026*
- Pulmonary Arterial Hypertension Therapeutics, Global, Clinical Trials by Trial Status, 2026*
- Pulmonary Arterial Hypertension Therapeutics Clinical Trials, Global, by End Point Status, 2026*
- Pulmonary Arterial Hypertension Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2021-2025
- Pulmonary Arterial Hypertension Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2026*
- Pulmonary Arterial Hypertension Therapeutics Clinical Trials, Global, Key Sponsors, 2026*
- Pulmonary Arterial Hypertension Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*
- Pulmonary Arterial Hypertension Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*
- The analyst Methodology
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Johnson & Johnson
- United Therapeutics Corp
- Bayer AG
- Thermo Fisher Scientific Inc
- Pfizer Inc
- Merck & Co Inc
- GSK plc
- ICON Plc
- Viatris Inc
- Gilead Sciences Inc
